BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Telomir-Zn Data Supporting Phase 1/2 TNBC Program

Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data showing Telomir-Zn suppressed tumor growth in prostate and triple-negative breast cancer (“TNBC”) models through selective modulation of intracellular iron and copper. Published in the Journal of Oncology Research and Therapy, the study showed Telomir-Zn inhibited histone demethylases by depleting intracellular iron, selectively killed iron-dependent TNBC cells while sparing […]